Evidence method
Level · gp.fundamentals.debt_to_revenue
83.86% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ARQT · Jun 30, 2026
Arcutis Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001787306-26-000051General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.12% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
9.73% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
59.33% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
29.94% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
91.58% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
12.65% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
15.67% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
9.83% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History10 statesHistory building
Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20250/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 103.82%
- Current
- 83.86%
- Delta
- -19.96%
- Previous
- 0.00%
- Current
- 0.12%
- Delta
- 0.12%
- Previous
- 2.12%
- Current
- 9.73%
- Delta
- 7.61%
- Previous
- 60.07%
- Current
- 59.33%
- Delta
- -0.74%
- Previous
- 35.48%
- Current
- 29.94%
- Delta
- -5.54%
- Previous
- 90.72%
- Current
- 91.58%
- Delta
- 0.86%
- Previous
- -8.62%
- Current
- 12.65%
- Delta
- 21.27%
- Previous
- 29.06%
- Current
- 15.67%
- Delta
- -13.38%
- Previous
- 10.14%
- Current
- 9.83%
- Delta
- -0.32%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Pharmaceutical Preparations peers →Derived From · ARQT Company Quality Vector →Transitioned To · ARQT Fundamental State →Transitioned To · ARQT BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ARQT CAPEX_INTENSITY_INCREASED →Transitioned To · ARQT CASH_GENERATION_INCREASED →Transitioned To · ARQT GROWTH_DECREASED →Transitioned To · ARQT INVENTORY_PRESSURE_DECREASED →Transitioned To · ARQT MARGIN_INCREASED →Transitioned To · ARQT PROFITABILITY_INCREASED →Transitioned To · ARQT R_AND_D_INTENSITY_DECREASED →Transitioned To · ARQT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.